---
title: "Crescent Biopharma 公佈 2025 年第二季度財務業績及近期業務亮點"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/251003846.md"
description: "完成與 GlycoMimetics 的合併，並已宣佈 2 億美元的私人融資，以支持下一代實體腫瘤治療藥物的研發管線……"
datetime: "2025-07-31T12:37:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251003846.md)
  - [en](https://longbridge.com/en/news/251003846.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251003846.md)
---

# Crescent Biopharma 公佈 2025 年第二季度財務業績及近期業務亮點

Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors ...

### 相關股票

- [GLYC.US](https://longbridge.com/zh-HK/quote/GLYC.US.md)
- [CBIO.US](https://longbridge.com/zh-HK/quote/CBIO.US.md)

## 相關資訊與研究

- [淺談 Snapdragon X2 Elite：見樹不見林？](https://longbridge.com/zh-HK/news/282461520.md)
- [中國水業訂重組契據，建議債務重組涉發行 5 批可換股債券還債](https://longbridge.com/zh-HK/news/282465828.md)
- [馬斯克 XChat 週五登陸 App Store](https://longbridge.com/zh-HK/news/282439803.md)
- [獨／國票金控股東大和解 公股與台鋼和人旺達成共識](https://longbridge.com/zh-HK/news/282773161.md)
- [壽險雙雄回來了！兩個月賣贏四年 OIU 保單強勢復活](https://longbridge.com/zh-HK/news/282444191.md)